Approved PLCO Projects
Here you can browse the complete list of projects for PLCO whose requests for data/biospecimens were approved.
| Name | Principal Investigator | Institution | Study | Date Approved | Project ID |
|---|---|---|---|---|---|
| Prostate specific antigen volatility and the diagnosis of clinically significant prostate cancer | John Leppert | Stanford University | PLCO | Aug 29, 2022 | PLCO-1034 |
| Metabolic health phenotypes, accelerated biological aging and cancer risk. | Prasoona Karra | Geisel School of Medicine at Dartmouth College | PLCO | Aug 29, 2022 | PLCO-1028 |
| Use of PLCO data to evaluate the performance of cancer risk models | Thomas Ahearn | Division of Cancer Genetics and Epidemiology, NCI | PLCO | Aug 22, 2022 | PLCO-1025 |
| Data Analysis of Male Breast Cancer | Vaidehi Gajera | Western Sydney University | PLCO | Aug 22, 2022 | PLCO-1029 |
| Identifying risk factors for depression and the role of depression in cancer | Lei Zhang | Uniformed Services University | PLCO | Aug 22, 2022 | PLCO-1027 |
| Prediction of Absolute Risk of Ovarian and Endometrial Cancer | Sokbom Kang | National Cancer Center, Korea | PLCO | Aug 22, 2022 | PLCO-1023 |
| Determination of the association between BDNF, a potential biomarker, and depression in patients with cancer | Lei Zhang | Uniformed Services University | PLCO | Aug 22, 2022 | PLCO-1021 |
| Fatty acids intake with emphasis on trans fatty acids and risks of Breast cancer and Colorectal Cancer | Paolo Boffetta | The Department of Medical and Surgical Sciences (DIMEC), the University of Bologna | PLCO | Aug 22, 2022 | PLCO-1018 |
| Bladder Cancer Data Visualization | OMAR GALDAMEZ CRUZ | CENTRO DE DISEÑO Y COMUNICACION, S.C. | PLCO | Aug 2, 2022 | PLCO-1011 |
| Prognostic factors in HER2-positive breast cancer | Reem Chamseddine | Weill Cornell Medicine-Qatar | PLCO | Aug 2, 2022 | PLCO-1014 |
| Clarifying the relationship between body mass index and lung cancer using causal inference methods | Rajat Das Gupta | University of South Carolina | PLCO | Aug 2, 2022 | PLCO-1010 |
| A Phase II extension of the use of cg05575921 Methylation to predict risk for lung cancer | Robert Philibert | Behavioral Diagnostics | PLCO | Aug 1, 2022 | 2022-0014 |
| Characterization of serum immuno-oncology biomarker levels in PLCO participants with mosaic chromosomal alterations | Mitchell Machiela | National Cancer Institute | PLCO | Aug 1, 2022 | 2022-0022 |
| Survival Analysis and the Effect of Censoring for Lung Cancer | Azar Shahraz | AstraZeneca | PLCO | Jul 22, 2022 | PLCO-991 |
| Identification of Risk Factors and Patient Populations at Risk for Developing Cancer of the Head and Neck | Jay Piccirillo | Washington University School of Medicine in St. Louis | PLCO | Jul 14, 2022 | PLCO-1003 |
| Screening for ovarian cancer in women with a personal or family history of breast or ovarian cancer | Nathan Bromham | National Institute for Health and Care Excellence | PLCO | Jul 12, 2022 | PLCO-1002 |
| Developing a multi-marker diagnostic test with predictive model enhancements for early-stage (Stage-1) Ovarian cancer | Srinagesh Satyanarayana | Kaya17 | PLCO | Jul 1, 2022 | PLCO-1000 |
| Expanded Genome-Wide Association Study of Renal Cell Carcinoma | Mark Purdue | Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health | PLCO | Jul 1, 2022 | PLCO-999 |
| Cancer risk prediction for self evaluation to create cancer awareness | Loise Mwarangu | Artificial Intelligence Center for Excellence | PLCO | Jul 1, 2022 | PLCO-993 |
| Sharing PLCO oncoarray genotyping and covariate data with the African Ancestry Breast Cancer Consortium | Thomas Ahearn | Division of Cancer Genetics and Epidemiology, NCI | PLCO | Jul 1, 2022 | PLCO-1001 |